MY149502A - Carrier composition for nucleic acid transport - Google Patents

Carrier composition for nucleic acid transport

Info

Publication number
MY149502A
MY149502A MYPI20081086A MYPI20081086A MY149502A MY 149502 A MY149502 A MY 149502A MY PI20081086 A MYPI20081086 A MY PI20081086A MY PI20081086 A MYPI20081086 A MY PI20081086A MY 149502 A MY149502 A MY 149502A
Authority
MY
Malaysia
Prior art keywords
nucleic acid
carrier
composition
carrier composition
delivery
Prior art date
Application number
MYPI20081086A
Other languages
English (en)
Inventor
Toyobuku Hidekazu
Miyao Hideo
Sato Masako
Sekiguchi Kazuo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MY149502A publication Critical patent/MY149502A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MYPI20081086A 2005-10-18 2006-10-17 Carrier composition for nucleic acid transport MY149502A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005303497 2005-10-18

Publications (1)

Publication Number Publication Date
MY149502A true MY149502A (en) 2013-09-13

Family

ID=37962449

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20081086A MY149502A (en) 2005-10-18 2006-10-17 Carrier composition for nucleic acid transport

Country Status (19)

Country Link
US (1) US8030075B2 (https=)
EP (1) EP1946761B8 (https=)
JP (1) JP5046952B2 (https=)
KR (1) KR101324065B1 (https=)
CN (2) CN101291678B (https=)
AR (1) AR057553A1 (https=)
AU (1) AU2006305318B2 (https=)
BR (1) BRPI0617449A2 (https=)
CA (1) CA2624840A1 (https=)
CY (1) CY1114586T1 (https=)
DK (1) DK1946761T3 (https=)
ES (1) ES2412029T3 (https=)
MY (1) MY149502A (https=)
PL (1) PL1946761T3 (https=)
PT (1) PT1946761E (https=)
RU (1) RU2421227C2 (https=)
SI (1) SI1946761T1 (https=)
TW (1) TW200800235A (https=)
WO (1) WO2007046356A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011114678A1 (ja) * 2010-03-15 2011-09-22 国立大学法人山口大学 哺乳動物細胞への遺伝子導入効率の向上剤
US9750819B2 (en) * 2012-05-23 2017-09-05 Ohio State Innovation Foundation Lipid nanoparticle compositions and methods of making and methods of using the same
US9833416B2 (en) * 2014-04-04 2017-12-05 Ohio State Innovation Foundation Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
EP3329011B1 (en) * 2015-07-30 2019-12-18 Arcis Biotechnology Holdings Limited Method and composition
CN117481114A (zh) * 2023-10-27 2024-02-02 硅羿科技(上海)有限公司 纳米核酸农药、其制备方法和应用、以及核酸递送系统

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6020317A (en) * 1993-02-19 2000-02-01 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US5965542A (en) * 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
DK1129064T3 (da) * 1998-11-12 2008-04-28 Invitrogen Corp Transfektionsreagenser
HUP9902217A3 (en) * 1999-06-29 2002-07-29 Szegoe Peter Polycation based bioconjugates and process for producing thereof
AU2002214854A1 (en) * 2000-10-25 2002-05-06 Inex Pharmaceuticals Corporation Lipid formulations for target delivery
WO2002060412A2 (en) * 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
EP1575976A4 (en) * 2001-11-02 2006-08-23 Insert Therapeutics Inc METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
ES2279127T3 (es) * 2002-07-05 2007-08-16 Lipoxen Technologies Limited Procedimiento para aumentar una respuesta inmunitaria de vacunacion de acido nucleico.
ES2559828T3 (es) * 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
AU2005310131A1 (en) * 2004-11-17 2006-06-08 University Of Maryland, Baltimore Highly branched HK peptides as effective carriers of siRNA
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport

Also Published As

Publication number Publication date
WO2007046356A1 (ja) 2007-04-26
EP1946761A1 (en) 2008-07-23
EP1946761A4 (en) 2012-01-25
CN101291678A (zh) 2008-10-22
CY1114586T1 (el) 2016-10-05
DK1946761T3 (da) 2013-04-15
US8030075B2 (en) 2011-10-04
RU2421227C2 (ru) 2011-06-20
EP1946761B1 (en) 2013-04-03
US20090258923A1 (en) 2009-10-15
KR20080059648A (ko) 2008-06-30
CA2624840A1 (en) 2007-04-26
JP5046952B2 (ja) 2012-10-10
AU2006305318A1 (en) 2007-04-26
CN102512689A (zh) 2012-06-27
PL1946761T3 (pl) 2013-08-30
SI1946761T1 (sl) 2013-06-28
EP1946761B8 (en) 2013-05-22
KR101324065B1 (ko) 2013-10-31
ES2412029T3 (es) 2013-07-09
PT1946761E (pt) 2013-05-27
AR057553A1 (es) 2007-12-05
TWI376225B (https=) 2012-11-11
RU2008119498A (ru) 2009-11-27
JPWO2007046356A1 (ja) 2009-04-23
AU2006305318B2 (en) 2011-08-25
HK1119956A1 (en) 2009-03-20
CN101291678B (zh) 2012-03-28
CN102512689B (zh) 2014-08-20
TW200800235A (en) 2008-01-01
BRPI0617449A2 (pt) 2011-07-26
HK1171689A1 (en) 2013-04-05

Similar Documents

Publication Publication Date Title
AU2017277731A1 (en) Hybrid carriers for Nucleic Acid cargo
PH12014500590A1 (en) Antimicrobial formulations with pelargonic acid
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
WO2010056970A3 (en) Optically-based stimulation of target cells and modifications thereto
MX2009003548A (es) Formulaciones que contienen lipidos.
MX2010005451A (es) Sistema para la liberacion en una celula positiva para xcr1 y usos de este.
EP3699280A3 (en) Novel cas9 systems and methods of use
WO2011133925A3 (en) Targeted and light-activated cytosolic drug delivery
WO2011035294A3 (en) Near infrared doped phosphors having an alkaline gallate matrix
MY151450A (en) Prompt nucleic acid delivery carrier composition
WO2012094574A3 (en) Stabilized polyribonucleotide nanoparticles
MX2009008542A (es) Agentes de suministro de acido fenilalquilcarboxilico.
MX2010003323A (es) Composiciones de poliplex de quitosana-acido nucleico de alta concentracion.
MX2023012040A (es) Lipidos ionizables y composiciones para la administracion de acido nucleico.
MY149502A (en) Carrier composition for nucleic acid transport
WO2009061003A3 (en) Nucleic acid complex and nucleic acid delivery composition
BR112015003730A2 (pt) sistema e método para transporte modular de um sistema de soldagem
ZA202207211B (en) Peptide docking vehicle for targeted nucleic acid delivery
WO2010019276A3 (en) Method and formulation for treating adverse biological conditions
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
WO2010045435A3 (en) Salicylic acid composition
WO2021141368A3 (ko) 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물
TH117335A (th) องค์ประกอบตัวพาให้ผลเร็วสำหรับการจ่ายกรดนิวคลีอิค
MX2011007776A (es) Compsiciones y metodos para inhibir la expresion de genes ptp1b.
TW200505482A (en) Lklf/klf2 gene expression promoters